Finally, Rite Aid declined another 7.5%. The drugstore chain continues to suffer from concerns expressed late last week that its proposed merger with Walgreens Boots Alliance ( WBA 0.79% ) might not go through as planned. Already, the stock trades more than $2 per share below the $9 merger price, reflecting considerable skepticism that Rite Aid's efforts to divest a substantial of its store base to a viable competitor will be enough to satisfy antitrust regulators. A termination of the merger would leave Rite Aid shareholders without the $9 per share price, and even the $325 million termination fee that Walgreens would owe Rite Aid if it can't get approval for the deal would only amount to about $0.30 per share of cash. With an already extended deadline between the two parties set to expire on Friday, Jan. 27, Rite Aid will have to move fast to avoid big problems ahead.